Pharmacogenomic Study

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery